4.3 Article

Identification of a novel specific small-molecule melanocortin-2-receptor antagonist

Journal

ENDOCRINE CONNECTIONS
Volume 11, Issue 12, Pages -

Publisher

BIOSCIENTIFICA LTD
DOI: 10.1530/EC-22-0338

Keywords

MRAP; MC2R; adrenal; GPCR antagonism; drug discovery

Funding

  1. International Fund for research on Congenital Adrenal Hyperplasia (IFCAH)
  2. British Society of Paediatric Endocrinology and Diabetes (BSPED)
  3. Barts and the London Charity [MGU0458]
  4. Medical Research Council (MRC) UK/Academy of Medical Sciences [G0802796]
  5. Wellcome Trust [217543/Z/19/Z]
  6. MRC [MR/J006394/1, MR/R015686/2442100]
  7. Wellcome Trust [217543/Z/19/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

The overproduction of ACTH leads to significant morbidity, but there is currently no effective medical treatment to directly block its action. This study identified a highly specific MC2R antagonist, providing a foundation for the clinical investigation of small-molecule ACTH antagonists as therapeutic agents.
The overproduction of adrenocorticotropic hormone (ACTH), in conditions such as Cushing's disease and congenital adrenal hyperplasia (CAH), leads to significant morbidity. Current treatment with glucocorticoids does not adequately suppress plasma ACTH, resulting in excess adrenal androgen production. At present, there is no effective medical treatment in clinical use that would directly block the action of ACTH. Such a therapy would be of great clinical value. ACTH acts via a highly selective receptor, the melanocortin-2 receptor (MC2R) associated with its accessory protein MRAP. ACTH is the only known naturally occurring agonist for this receptor. This lack of redundancy and the high degree of ligand specificity suggest that antagonism of this receptor could provide a useful therapeutic strategy in the treatment of conditions of ACTH excess. To this end, we screened an extensive library of low-molecular-weight drug-like compounds for MC2R antagonist activity using a high-throughput homogeneous time-resolved fluorescence cAMP assay in Chinese hamster ovary cells stably co-expressing human MC2R and MRAP. Hits that demonstrated MC2R antagonist properties were counter-screened against the beta 2 adrenergic receptor and dose-response analysis undertaken. This led to the identification of a highly specific MC2R antagonist capable of antagonising ACTH-induced progesterone release in murine Y-1 adrenal cells and having selectivity for MC2R amongst the human melanocortin receptors. This work provides a foundation for the clinical investigation of small-molecule ACTH antagonists as therapeutic agents and proof of concept for the screening and discovery of such compounds.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available